Nieto, Y., Nawaz, S. and Cagnoni, P.J. (1999) Overexpression of Her 2/Neu (H2N), But Not P53 Mutations Is a Poor Prognostic Factor of High-Risk Primary Breast Cancer (HRPBC) Treated with High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplant (ASCT). Proceedings of American Society of Clinical Oncology, 18, Abstract 290.

has been cited by the following article:

• TITLE: Occurrence Delays of Metastatic Relapses of Breast Cancers Treated at University Hospital of Treichville (Abidjan-Cote d’Ivoire)

  AUTHORS: Lydie Estelle Djanhan, Jean Marc Dia, Boston Mian, Mouhideen Oyelade, Aboulaye Diallo, Privat Guié, Simplice Anongba

  KEYWORDS: Breast Cancer, Risk Factors, Metastatic Relapses

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.11, November 13, 2017

  ABSTRACT: Objective: Describe the occurrence delays of metastatic relapses of breast cancer based on the characteristics of the original tumor. Methodology: This is a retrospective and cohort study conducted from January 2000 to December 2015 on patients with metastatic relapse of breast cancer. Results: Out of 178 patients collected, the metastatic relapses were estimated at 49%, occurring in patients with an average age of 53.4 years. The majority of the patients was educated (91.6%) and did not have a high socioeconomic level (88.2%). The initial tumors were mainly at a clinical stage III (47.8%), SBR grade III (47.2%), high index Ki 67 (46.5%), negative RH (79.3%) and HER2 negative (58%). Metastases were unique in general (62.9%), dominated by bone locations (36.6%), with an average age of occurrence of 2.4 years. After the occurrence of these metastases, the cumulative survival rate was 5% at 3 years, and zero to 5 years. Conclusion: Metastatic relapses were common with poor prognosis.